Published in Med Decis Making on December 30, 2009
An algorithm to identify patients with treated type 2 diabetes using medico-administrative data. BMC Med Inform Decis Mak (2011) 0.99
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2006) 9.87
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70
Effect of ramipril on the incidence of diabetes. N Engl J Med (2006) 9.69
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int (2003) 5.37
Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet (2010) 4.42
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38
Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes (2006) 4.13
Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet (2010) 3.92
Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care (2002) 3.62
Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care (2008) 3.45
Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol (2004) 3.38
Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. Am Heart J (2006) 2.87
Randomized trial to compare bilateral vs. single internal mammary coronary artery bypass grafting: 1-year results of the Arterial Revascularisation Trial (ART). Eur Heart J (2010) 2.67
The effect of glibenclamide on insulin secretion at normal glucose concentrations. Diabetologia (2014) 1.98
Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care (2007) 1.91
Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Med Decis Making (2006) 1.89
Effect of urgent treatment for transient ischaemic attack and minor stroke on disability and hospital costs (EXPRESS study): a prospective population-based sequential comparison. Lancet Neurol (2009) 1.87
Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61. Diabetes Care (2002) 1.85
Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care (2005) 1.81
Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. Diabetes (2006) 1.75
Performance of the UK Prospective Diabetes Study Risk Engine and the Framingham Risk Equations in Estimating Cardiovascular Disease in the EPIC- Norfolk Cohort. Diabetes Care (2008) 1.70
Prognostic significance of silent myocardial infarction in newly diagnosed type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 79. Circulation (2013) 1.60
Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med (2010) 1.59
A longitudinal study of the effects of age and time to death on hospital costs. J Health Econ (2004) 1.53
Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT. Diabetes (2011) 1.53
UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care (2002) 1.53
Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care (2004) 1.51
Costs of stroke using patient-level data: a critical review of the literature. Stroke (2008) 1.50
A standardized triglyceride and carbohydrate challenge: the oral triglyceride tolerance test. Diabetes Care (2004) 1.50
Development of life-expectancy tables for people with type 2 diabetes. Eur Heart J (2008) 1.44
Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab (2009) 1.41
Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension on clinical end points: a cohort study. J Clin Hypertens (Greenwich) (2012) 1.40
How fair is Medicare? The income-related distribution of Medicare benefits with special focus on chronic care items. Med J Aust (2012) 1.39
Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J Diabetes Complications (2006) 1.30
A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care (2002) 1.24
Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study 78. Circulation (2007) 1.23
Population-based study of determinants of initial secondary care costs of acute stroke in the United Kingdom. Stroke (2006) 1.20
Screening for cervical cancer in India: How much will it cost? A trial based analysis of the cost per case detected. Int J Cancer (2005) 1.18
Can self-rated health scores be used for risk prediction in patients with type 2 diabetes? Diabetes Care (2008) 1.18
A population-based study of hospital care costs during 5 years after transient ischemic attack and stroke. Stroke (2012) 1.15
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J (2013) 1.09
Quality of life after TIA and stroke: ten-year results of the Oxford Vascular Study. Neurology (2013) 1.08
Population-based study of disability and institutionalization after transient ischemic attack and stroke: 10-year results of the Oxford Vascular Study. Stroke (2013) 1.07
Estimating equations to correct self-reported height and weight: implications for prevalence of overweight and obesity in Australia. Aust N Z J Public Health (2008) 1.05
Challenges and opportunities for the Pharmaceutical Benefits Scheme. Med J Aust (2012) 1.05
Change in bias in self-reported body mass index in Australia between 1995 and 2008 and the evaluation of correction equations. Popul Health Metr (2011) 1.04
Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clin J Am Soc Nephrol (2011) 1.01
Cost of dementia in the pre-enlargement countries of the European Union. J Alzheimers Dis (2011) 0.96
The variable number of tandem repeats upstream of the insulin gene is a susceptibility locus for latent autoimmune diabetes in adults. Diabetes (2006) 0.96
Population-based study of acute- and long-term care costs after stroke in patients with AF. Int J Stroke (2012) 0.95
The impact of individualised cardiovascular disease (CVD) risk estimates and lifestyle advice on physical activity in individuals at high risk of CVD: a pilot 2 x 2 factorial understanding risk trial. Cardiovasc Diabetol (2008) 0.95
Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT). Diabetes Care (2009) 0.94
Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes. Curr Opin Lipidol (2009) 0.93
Estimating utility values for health states of overweight and obese individuals using the SF-36. Qual Life Res (2005) 0.91
A meta-analysis of health state valuations for people with diabetes: explaining the variation across methods and implications for economic evaluation. Qual Life Res (2011) 0.89
Use of focus groups to develop methods to communicate cardiovascular disease risk and potential for risk reduction to people with type 2 diabetes. Fam Pract (2009) 0.86
Evaluation of a self-administered oral glucose tolerance test. Diabetes Care (2013) 0.86
Assessing the impact of visual acuity on quality of life in individuals with type 2 diabetes using the short form-36. Diabetes Care (2006) 0.84
Cost-effectiveness of artemisinin combination therapy for uncomplicated malaria in children: data from Papua New Guinea. Bull World Health Organ (2011) 0.84
The cost-effectiveness of residential radon remediation programmes: assumptions about benefits stream profiles over time. J Environ Radioact (2002) 0.84
Hospitalization resource use and costs before and after TIA and stroke: results from a population-based cohort study (OXVASC). Value Health (2013) 0.83
Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials. Cardiovasc Ther (2010) 0.82
Presenting the results of clinical trials to participants. Clin Med (2009) 0.82
Simulating lifetime outcomes associated with complications for people with type 1 diabetes. Pharmacoeconomics (2013) 0.81
Predicting Changes in Cardiovascular Risk Factors in Type 2 Diabetes in the Post-UKPDS Era: Longitudinal Analysis of the Swedish National Diabetes Register. J Diabetes Res (2013) 0.81
UKPDS58--modeling glucose exposure as a risk factor for photocoagulation in type 2 diabetes. J Diabetes Complications (2002) 0.81
Initiating insulin as part of the Treating To Target in Type 2 Diabetes (4-T) trial: an interview study of patients' and health professionals' experiences. Diabetes Care (2010) 0.80
Temporal validation of the UKPDS outcomes model using 10-year posttrial monitoring data. Diabetes Care (2012) 0.80
Adapting and validating diabetes simulation models across settings: accounting for mortality differences using administrative data. J Diabetes Complications (2013) 0.79
Simulation of quality-adjusted survival in chronic diseases: an application in type 2 diabetes. Med Decis Making (2011) 0.79
Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. Stroke (2013) 0.78
Comparability of patient-reported health status: multicountry analysis of EQ-5D responses in patients with type 2 diabetes. Med Care (2011) 0.77
Perceptions of heart attack risk amongst individuals with diabetes. Prim Care Diabetes (2009) 0.77
Primary prevention of cardiovascular events in diabetes: is there a role for aspirin? Nat Clin Pract Cardiovasc Med (2009) 0.76
Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 0.75
A clinical screening tool identifies autoimmune diabetes in adults: response to Fourlanos et al. Diabetes Care (2006) 0.75
Prediabetes and the risk of diabetes. Lancet (2012) 0.75
Within-class differences of the sulfonylureas should be accounted for. Reply to Schrijnders D, Kleefstra N and Landman GWD [letter]. Diabetologia (2015) 0.75
The pricing of statins and implications for Pharmaceutical Benefits Scheme expenditure. Med J Aust (2013) 0.75
New BMJ policy on economic evaluations. Economic evaluations should be judged on scientific merit. BMJ (2003) 0.75
A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk. Am J Cardiol (2013) 0.75
Preface - Diabetes prevention and management. Best Pract Res Clin Endocrinol Metab (2016) 0.75